BlackRock
IMRX icon

BlackRock’s Immuneering IMRX Stock Holding History

BlackRock’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8M Buy
4,374,020
+2,866,762
+190% +$14.5M ﹤0.01% 3193
2026
Q1 		$7.94M Buy
1,507,258
+55,552
+4% +$285K ﹤0.01% 3636
2025
Q4 		$9.55M Buy
1,451,706
+770,521
+113% +$4.95M ﹤0.01% 3501
2025
Q3 		$4.77M Buy
681,185
+258,427
+61% +$1.34M ﹤0.01% 3799
2025
Q2 		$1.42M Buy
422,758
+106,228
+34% +$182K ﹤0.01% 4149
2025
Q1 		$481K Sell
316,530
-2,233
-0.7% -$4.06K ﹤0.01% 4412
2024
Q4 		$701K Buy
318,763
+344
+0.1% +$713 ﹤0.01% 4320
2024
Q3 		$793K Sell
318,419
-214,945
-40% -$313K ﹤0.01% 4228
2024
Q2 		$683K Sell
533,364
-843,756
-61% -$1.39M ﹤0.01% 4272
2024
Q1 		$3.98M Sell
1,377,120
-720,286
-34% -$4.04M ﹤0.01% 3767
2023
Q4 		$15.4M Sell
2,097,406
-414,612
-17% -$2.76M ﹤0.01% 3151
2023
Q3 		$19.3M Buy
2,512,018
+88,360
+4% +$812K ﹤0.01% 2960
2023
Q2 		$24.6M Buy
2,423,658
+1,083,465
+81% +$10.4M ﹤0.01% 2902
2023
Q1 		$13M Sell
1,340,193
-8,191
-0.6% -$46.5K ﹤0.01% 3181
2022
Q4 		$6.54M Sell
1,348,384
-75,650
-5% -$670K ﹤0.01% 3595
2022
Q3 		$20.4M Buy
1,424,034
+67,364
+5% +$535K ﹤0.01% 3020
2022
Q2 		$7.34M Sell
1,356,670
-766,704
-36% -$4.09M ﹤0.01% 3653
2022
Q1 		$13.7M Buy
2,123,374
+407,204
+24% +$3.91M ﹤0.01% 3401
2021
Q4 		$27.8M Buy
1,716,170
+191,796
+13% +$4.67M ﹤0.01% 3066
2021
Q3 		$40.5M Buy
+1,524,374
New +$41M ﹤0.01% 2800

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

BlackRock's IMRX Position: Q2 2026 in Review

BlackRock increased its Immuneering (IMRX) stake by 190% in Q2 2026, buying an estimated $14.5M and bringing the position to 4,374,020 shares worth $21.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3193.

BlackRock first reported a position in IMRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $40.5M in Q3 2021. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • BlackRock held 4,374,020 shares of Immuneering worth $21.8M as of Q2 2026.
  • BlackRock bought 2,866,762 Immuneering shares in Q2 2026, an estimated $14.5M.
  • Immuneering made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3193 holding.
  • BlackRock first reported a position in Immuneering in Q3 2021 and has held it in 20 quarters since.
  • BlackRock's Immuneering position peaked at $40.5M in Q3 2021.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.